User Tools

Site Tools


triaging_pdl1_3d_requests

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
triaging_pdl1_3d_requests [2026/04/07 20:33] gilberttriaging_pdl1_3d_requests [2026/04/07 20:40] (current) – removed gilbert
Line 1: Line 1:
  
- 
-===== Gastrointestinal Biomarkers ===== 
-<WRAP div width-100%> 
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^ 
-| **PD-L1** | Gastric, GEJ, esophageal adenocarcinoma; ESCC | Pembrolizumab, Nivolumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1UPPERGIMARCH2026.pdf | ''PDL1UPPERGIMARCH2026''}} | 
-| **Claudin 18.2** | Gastric or GEJ adenocarcinoma | Zolbetuximab | VENTANA CLDN18 (43-14A) %%RxDx%% | {{media:biomarkers:BMCLAUDIN18.pdf | ''BMCLAUDIN18''}} | 
-</WRAP> 
- 
-===== Head & Neck Biomarkers ===== 
-<WRAP div width-100%> 
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^ 
-| **PD-L1** | **Advanced** HNSCC | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1HNSCC22C3PEMBRO.pdf | ''PDL1HNSCC22C3PEMBRO''}} | 
-| **PD-L1** | **Resectable** HNSCC | Pembrolizumab as **Neoadjuvant** | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1HNSCCNEOADPEMBRO.pdf | ''PDL1HNSCCNEOADPEMBRO''}} | 
-</WRAP> 
- 
-===== Gyne Biomarkers ===== 
-<WRAP div width-100%> 
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^ 
-| **PD-L1** | Cervical cancer (SCC and Adenocarcinoma) | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1CERVIX.pdf | ''PDL1CERVIX''}} | 
-| **CEP17 SISH** | Ploidy Analysis | N/A | VENTANA Inform Chromosome 17 probe | {{media:biomarkers:MOLARCEP17.pdf | ''MOLARCEP17''}} | 
-</WRAP> 
- 
-===== Lung Biomarkers ===== 
-<WRAP div width-100%> 
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^ 
-| **PD-L1** | NSCLC stage IIIb to IV | Pembrolizumab | PDL1 22C3 | {{media:biomarkers:PDL1NSCLCPEMBRO22C3.pdf | ''PDL1NSCLCPEMBRO22C3''}} | 
-| **PD-L1** | NSCLC stage II to IIIA | Atezolizumab as **Adjuvant** | PDL1 SP263 | {{media:biomarkers:PDL1NSCLCATEZOSP263.pdf | ''PDL1NSCLCATEZOSP263''}} | 
-</WRAP> 
- 
-===== Breast Biomarkers ===== 
-<WRAP div width-100%> 
-^ Biomarker ^ Assay Purpose ^ Drug(s) ^ Diagnostic Test ^ Test ID ^ 
-| **PD-L1** | Triple Negative Breast Cancer (TNBC) | Pembrolizumab | PDL1 Dako 22C3 %%PharmDX%% | {{media:biomarkers:PDL1TNBC22C3PEMBRO.pdf | ''PDL1TNBC22C3PEMBRO''}} | 
-</WRAP> 
triaging_pdl1_3d_requests.1775594007.txt.gz · Last modified: by gilbert

Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki